
Search
Selected Filter
Filter Results
Displaying 121–130 of 504 news results
-
Aug 25, 2022
Belite Bio Launching Phase 3 Clinical Trial for Stargardt Disease Drug
The company’s drug is designed to reduce accumulation of toxins that cause vision loss.
-
Aug 11, 2022
ProQR Seeking to Partner Ophthalmic Programs
The company is halting its clinical programs for LCA10 and USH2A as it seeks a new partner
-
Aug 10, 2022
Funding for the new grants was made possible by Foundation’s strong donor base and philanthropic partners
-
Jul 29, 2022
Progress toward a stem cell–based therapy for blindness
A multi-institutional effort led by researchers at the School of Veterinary Medicine is taking steps to develop an effective technique to regenerate photoreceptors cells and restore sight in people with vision disorders.
-
Jul 25, 2022
The emerging therapy is designed to restore vision for people with advanced retinal degenerative diseases
-
Jul 22, 2022
Apellis’ Treatment for Advanced Dry AMD to Receive Priority Review from FDA
There are currently no FDA-approved therapies for geographic atrophy (GA), the advanced form of dry AMD.
-
Jul 21, 2022
RD Fund Announces New Chair, and Expansion of Board of Directors
RD Fund Board member and seasoned ophthalmology leader Adrienne Graves, PhD, appointed chair. Ophthalmology luminaries Jean Bennett, MD, PhD, Catherine Bowes Rickman, PhD, and José-Alain Sahel, MD, to join the board.
-
Jul 14, 2022
Endogena Launches Clinical Trial of Therapy to Activate Stem Cells in RP Patients’ Retinas
The emerging treatment is gene-agnostic.
-
Jun 27, 2022
Kiora to Launch Clinical Trial in Australia for Vision-Restoring Small Molecule for RP Patients
The approach bestows light sensitivity to retinal ganglion cells for people who have lost their photoreceptors
-
Jun 21, 2022
Foundation Fighting Blindness Announces Leadership Changes
Jason Menzo named chief executive officer • Russell Kelley, PhD, MBA, appointed managing director of the RD Fund • Ben Yerxa, PhD, to lead Opus Genetics, the first RD Fund- and Foundation-backed spin-off company.